- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02966756
A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
A Phase 2 Open-Label Study of the Efficacy of Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: ABBVIE CALL CENTER
- Phone Number: 844-663-3742
- Email: abbvieclinicaltrials@abbvie.com
Study Locations
-
-
New South Wales
-
Concord, New South Wales, Australia, 2139
- Recruiting
- Concord Repatriation General Hospital /ID# 201261
-
Kogarah, New South Wales, Australia, 2217
- Recruiting
- St George Hospital /ID# 206484
-
-
Victoria
-
Clayton, Victoria, Australia, 3168
- Recruiting
- Monash Medical Centre /ID# 201263
-
-
-
-
Anhui
-
Hefei, Anhui, China, 230031
- Recruiting
- Anhui Provincial Cancer Hospital /ID# 209458
-
-
Beijing
-
Beijing, Beijing, China, 100044
- Recruiting
- Peking University People's Hospital /ID# 156575
-
Beijing, Beijing, China, 100730
- Recruiting
- Peking Union Medical College Hospital /ID# 156576
-
-
Fujian
-
Fuzhou, Fujian, China, 350001
- Recruiting
- Fujian Medical University Union Hospital /ID# 156579
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510080
- Recruiting
- Guangdong Provincial People's Hospital /ID# 160509
-
Guangzhou, Guangdong, China, 510515
- Recruiting
- Nanfang Hospital of Southern Medical University /ID# 156571
-
-
Hebei
-
Shijiazhuang, Hebei, China, 050000
- Completed
- The Second Hospital of Hebei Medical University /ID# 159143
-
-
Henan
-
Zhengzhou, Henan, China, 450008
- Recruiting
- Henan Cancer Hospital /ID# 156573
-
-
Hubei
-
Wuhan, Hubei, China, 430030
- Recruiting
- Tongji Hospital Tongji Medical College of HUST /ID# 156589
-
-
Hunan
-
Changsha, Hunan, China, 410008
- Recruiting
- Xiangya Hospital Central South University /ID# 208913
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210029
- Recruiting
- Jiangsu Province Hospital /ID# 156577
-
Suzhou, Jiangsu, China, 215006
- Recruiting
- The First Affiliated Hospital of Soochow University /ID# 156536
-
-
Jiangxi
-
Nanchang, Jiangxi, China, 330006
- Recruiting
- The First Affiliated Hospital of Nanchang University /ID# 159142
-
-
Jilin
-
Changchun, Jilin, China, 130021
- Recruiting
- The First Hospital of Jilin University /ID# 156532
-
-
Shandong
-
Jinan, Shandong, China, 250021
- Recruiting
- Shandong Provincial Hospital /ID# 156574
-
-
Shanghai
-
Shanghai, Shanghai, China, 200065
- Recruiting
- Ruijin Hospital, Shanghai Jiaotong University School of Medicine /ID# 156572
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- Recruiting
- West China Hospital, Sichuan University /ID# 156537
-
Chengdu, Sichuan, China, 610083
- Recruiting
- The General Hospital of Western Theater Command PLA /ID# 159145
-
-
Tianjin
-
Tianjin, Tianjin, China, 300020
- Recruiting
- Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc /ID# 157762
-
Tianjin, Tianjin, China, 300060
- Recruiting
- Tianjin Medical University Cancer Institute & Hospital /ID# 156542
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310003
- Recruiting
- The First Affiliated Hospital, Zhejiang University School of Medicine /ID# 156578
-
-
-
-
Auckland
-
Takapuna, Auckland, New Zealand, 0622
- Recruiting
- North Shore Hospital /ID# 204637
-
-
Canterbury
-
Christchurch, Canterbury, New Zealand, 8011
- Recruiting
- Christchurch Hospital /ID# 201650
-
-
-
-
-
Changhua City, Changhua County, Taiwan, 50006
- Completed
- Changhua Christian Hospital /ID# 202768
-
Kaohsiung, Taiwan, 807
- Recruiting
- Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 202765
-
Taichung, Taiwan, 40447
- Recruiting
- China Medical University Hospital /ID# 202767
-
Taipei City, Taiwan, 100
- Recruiting
- National Taiwan University Hospital /ID# 210733
-
Taoyuan City, Taiwan, 333
- Recruiting
- Linkou Chang Gung Memorial Hospital /ID# 203636
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Participant must have a diagnosis of relapsed or refractory chronic lymphocytic leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) that meets 2008 Modified International Workshop for Chronic Lymphocytic Leukemia (iwCLL) National Cancer Institute-Working Group (NCI-WG) Guidelines and the following:
- Participant must have an indication for treatment according to the 2008 Modified iwCLL NCI-WG Guidelines.
- SLL participant must have measurable disease (B-lymphocytosis greater than 5 × 10^9/L or an enlarged lymph node(s) (Longest Diameter (LDi) > 1.5 cm at baseline) or hepatomegaly or splenomegaly due to CLL).
- SLL participant must have presence of lymphadenopathy and absence of cytopenias caused by a clonal marrow infiltrate.
- Participant must have relapsed or refractory CLL/SLL after receiving at least one prior line of therapy.
- Participants (in Cohort 1) must have 17p deletion, assessed by a central laboratory.
Participants (in Cohort 2) must meet both of the following:
- Relapsed/refractory disease to B-Cell Receptor Signaling Pathway Inhibitor (BCRI) treatment;
- And either of the following: (a) relapsed/refractory disease to chemoimmunotherapy (CIT), or (b) ineligible to receive CIT, defined as having known 17p deletion or TP53 mutation, or Cumulative Illness Rating Scale (CIRS) >6 or calculated creatinine clearance <70 mL/min, or participants in whom the investigator evaluated that the use of CIT was inappropriate.
- Participant must have an Eastern Cooperative Oncology Group (ECOG) performance score of less than or equal to 2.
- Participant must have adequate bone marrow function, coagulation profile, renal, and hepatic function, per laboratory reference range at Screening.
- No known active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
Exclusion Criteria:
- Participant has undergone an allogeneic stem cell transplant.
- Participant has developed Richter's transformation confirmed by biopsy.
- Participant has prolymphocytic leukemia.
- Participant has active and uncontrolled autoimmune cytopenias (for 2 weeks prior to screening), including autoimmune hemolytic anemia (AIHA) and idiopathic thrombocytopenic purpura (ITP).
- Participant has previously received venetoclax.
- Participant is known to be positive for Human Immunodeficiency Virus (HIV).
- Participant has received a biologic agent for anti-neoplastic intent within 30 days prior to the first dose of study drug.
Participant has received any of the following within 14 days or 5 half-lives (whichever is shorter) prior to the first dose of venetoclax, or has not recovered to less than Common Toxicity Criteria for Adverse Events (CTCAE) grade 2 clinically significant adverse effect(s)/toxicity(s) of the previous therapy:
- Any anti-cancer therapy including chemotherapy, immunotherapy, radiotherapy or targeted small molecule agents.
- Investigational therapy, including targeted small molecule agents.
- Participant has known allergy to both xanthine oxidase inhibitors and rasburicase.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1: Venetoclax
Participants with 17p deletion status will receive various doses of venetoclax once daily (QD).
|
Tablet; Oral
Other Names:
|
Experimental: Cohort 2: Venetoclax
Participants who have failed a B-Cell Receptor Signaling Pathway Inhibitor (BCRI) therapy and who have also failed, or were unable to receive chemoimmunotherapy (CIT) irrespective of 17p status will receive various doses of venetoclax once daily (QD).
|
Tablet; Oral
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Response Rate (ORR)
Time Frame: Measured up to 2 years after the last participant has enrolled in the study.
|
ORR is the proportion of participants with an overall response (complete remission [CR], plus complete remission with incomplete bone marrow recovery [CRi], plus nodular partial remission [nPR], plus partial remission [PR]) per the National Cancer Institute-Working Group (NCI-WG) guidelines as assessed by the Independent Review Committee (IRC).
|
Measured up to 2 years after the last participant has enrolled in the study.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of Overall Response (DOR)
Time Frame: Measured up to 2 years after the last participant has enrolled into the study.
|
DOR is defined as the number of days from the date of first (CR + CRi + nPR + PR) to the earliest disease progression or death
|
Measured up to 2 years after the last participant has enrolled into the study.
|
Progression Free Survival (PFS)
Time Frame: Measured up to 5 years after the last participant has enrolled into the study.
|
PFS is defined as the number of days from the date of first dose to the date of earliest disease progression (determined by the IRC) or death.
|
Measured up to 5 years after the last participant has enrolled into the study.
|
Event Free Survival (EFS)
Time Frame: Measured up to 5 years after the last participant has enrolled into the study.
|
EFS is defined as the number of days from the date of first dose to the date of earliest disease progression, death, or start of a new anti-leukemic therapy.
|
Measured up to 5 years after the last participant has enrolled into the study.
|
Time to Progression (TTP)
Time Frame: Measured up to 5 years after the last participant has enrolled into the study.
|
TTP is defined as the number of days from the date of first dose to the date of earliest disease progression (determined by the IRC).
|
Measured up to 5 years after the last participant has enrolled into the study.
|
Overall Survival (OS)
Time Frame: Measured up to 5 years after the last participant has enrolled into the study.
|
OS is defined as number of days from the date of first dose to the date of death.
|
Measured up to 5 years after the last participant has enrolled into the study.
|
Complete Response Rate (CRR)
Time Frame: Measured up to 2 years after the last participant has enrolled into the study.
|
CRR is defined as the proportion of subjects who achieved (CR + CRi) per the 2008 Modified International Workshop for Chronic Lymphocytic Leukemia (iwCLL) NCI-WG criteria.
|
Measured up to 2 years after the last participant has enrolled into the study.
|
Time to 50% reduction in absolute lymphocyte count (ALC)
Time Frame: Measured up to 2 years after the last participant has enrolled into the study.
|
Time to 50% reduction in ALC is defined as the number of days from the date of first dose to the date when the ALC has reduced to 50% of the baseline value.
|
Measured up to 2 years after the last participant has enrolled into the study.
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: ABBVIE INC., AbbVie
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Disease Attributes
- Hematologic Diseases
- Leukemia, B-Cell
- Chronic Disease
- Lymphoma
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Antineoplastic Agents
- Venetoclax
Other Study ID Numbers
- M14-728
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Lymphocytic Leukemia (CLL)
-
AbbVieRecruitingCancer, Chronic Lymphocytic Leukemia (CLL)Korea, Republic of
-
Hackensack Meridian HealthCelgene CorporationTerminatedSmall Lymphocytic Lymphoma | Chronic Lymphocytic Leukemia(CLL)United States
-
Piramal Enterprises LimitedDana-Farber Cancer Institute; Norris Cotton Cancer CenterSuspendedRelapsed/Refractory Chronic Lymphocytic Leukemia (CLL)United States
-
Virginia Commonwealth UniversityGilead SciencesWithdrawnChronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | CLL | Refractory Small Lymphocytic Lymphoma | SLL | Relapsed CLL | Relapsed Chronic Lymphocytic Leukemia | Relapsed Small Lymphocytic Lymphoma
-
Tampere University HospitalCompleted
-
AstraZenecaRecruitingChronic Lymphocytic Leukaemia (CLL)Germany
-
University of California, IrvineUnited States Department of DefenseActive, not recruitingAcute Myeloid Leukemia | Chronic Lymphocytic Leukemia | AML, Adult | CLL | CLL, Relapsed | CLL, RefractoryUnited States
-
Memorial Sloan Kettering Cancer CenterPharmacyclics LLC.WithdrawnChronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | CLL | CLL/SLL | SLLUnited States
-
Novartis PharmaceuticalsCompletedChronic Lymphocytic Leukemia (CLL) | Leukaemia, Lymphocytic, ChronicUnited States, Belgium, Italy, Greece, Russian Federation, Spain, Poland, Czech Republic
-
AstraZenecaCLL ConsortiumCompletedB Cell Lymphomas | 11q-deleted Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL), | Prolymphocytic Leukaemia (PLL)United States
Clinical Trials on Venetoclax
-
Virginia Commonwealth UniversityAbbVieWithdrawnRelapsed Small Cell Lung Cancer | Refractory Small Cell Lung Carcinoma
-
PrECOG, LLC.Genentech, Inc.CompletedFollicular Lymphoma | Non-Hodgkin's Lymphoma Follicular | Non-Hodgkin's Lymphoma, Adult High GradeUnited States
-
University of Maryland, BaltimoreActive, not recruitingRelapsed or Refractory Acute Myeloid LeukemiaUnited States
-
Yale UniversityCompleted
-
Gruppo Italiano Malattie EMatologiche dell'AdultoRecruiting
-
Stichting Hemato-Oncologie voor Volwassenen NederlandNordic Lymphoma GroupActive, not recruiting
-
Stichting Hemato-Oncologie voor Volwassenen NederlandNordic CLL Study GroupActive, not recruitingChronic Lymphocytic Leukemia in Relapse | Chronic Lymphocytic Leukemia in RemissionNetherlands, Belgium, Denmark, Finland, Norway, Sweden
-
BioSight Ltd.Recruiting
-
The Lymphoma Academic Research OrganisationInstitute of Cancer Research, United KingdomRecruitingMantle Cell LymphomaFrance, United Kingdom, Belgium
-
Aptose Biosciences Inc.RecruitingRelapsed or Refractory Acute Myeloid LeukemiaUnited States, Germany, Spain, Korea, Republic of, Australia, New Zealand